Investors


Medicxi

Medicxi is based in London, Geneva and Jersey. The firm's mission is to invest across the full healthcare continuum. Medicxi was established by the former Index Ventures life sciences team and continues to manage the legacy life sciences portfolio of Index Ventures. Medicxi has also recently launched two new funds - Medicxi Ventures 1 (MV1) and Medicxi Growth 1 (MG1) – that focus respectively on early-stage and late-stage investments in life sciences.

GSK, Johnson & Johnson and Novartis, three of the world’s largest pharmaceutical companies back Medicxi along with Verily, an Alphabet company. These companies, whilst participating in the SABs of the Medicxi funds, do not receive any preferential rights to the portfolio companies.

Medicxi’s team has been investing in life sciences for over 20 years and has backed many successful companies, including Genmab (NASDAQ Copenhagen: GEN), PanGenetics (sold to AbbVie), Micromet (sold to Amgen), Molecular Partners (SWX: MOLN), XO1 (sold to Janssen), Minerva Neurosciences (NASDAQ: NERV), Padlock Therapeutics (sold to Bristol-Myers Squibb) and Impact Biomedicines (sold to Celgene).

Please see www.medicxi.com for more information.


RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes in a continual effort to put data into context, identify breakthroughs, and originate conviction in new ideas.

Please visit http://racapitalmanagement.com for more information.


SanquinSanquin thumb

Sanquin Blood Supply Foundation ensures the safe and efficient blood supply in the Netherlands. Sanquin also develops and produces pharmaceutical products, conducts highquality scientific research relating to blood transfusion medicine and immunology in the broadest sense, and develops and performs a multitude of diagnostic services.

Sanquin Blood Supply Foundation
Mr. Robert Heckert
T: +31 20 512 3000
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.sanquin.nl


PPM Oost & IIGPPM thumb

Participatiemaatschappij Oost Nederland NV (PPM Oost) invests public money in promising companies that are contributing to a flourishing economy in the East Netherlands, especially in the food, health and technology sectors. PPM Oost has invested in more than 150 companies. PPM Oost also manages and executes the Provincial Innovation and Investment Fund Gelderland (IIG), a recently established revolving fund that focuses on the strategic areas Food, Health, Energy and Environmental Technology.

PPM Oost/IIG B.V.
Mr. Pieter Rhemrev
T: +31 26 384 40 44
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.ppmoost.nl


Stichting Participation Xenikos

A trust fund representing a number of knowledgeable private investors, including current and former biopharmaceutical executives and a life sciences fund manager.

Stichting Participation Xenikos
Ir. Paul Lelieveld
T: +31 6 46 23 23 57
E:
This email address is being protected from spambots. You need JavaScript enabled to view it.


Netherlands Enterprise Agency (RVO)
Agentschap thumband the Innovation Credit Scheme

The Netherlands Enterprise Agency (RVO) is an agency of the Dutch Ministry of Economic Affairs, Agriculture and Innovation that promotes sustainable development and innovation with various financial instruments. The Innovation Credit is aimed at supporting high risk, and commercially attractive, technical or clinical development projects.

Netherlands Enterprise Agency (RVO)
Drs. Elisabeth Schless
T: +31 88 602 4631
E:
This email address is being protected from spambots. You need JavaScript enabled to view it.
W: www.innovatiekrediet.nl

 

Partner


Radboudumc

Radboud thumb

The Radboud University Medical Center in Nijmegen is an institution where delivering quality on an international level is paramount. The Radboud University is active in four science domains: alpha, beta, gamma and medical. All four are fully anchored in and involved in society. Close to 20,000 students are enrolled in the Radboud University and the Radboudumc combined. The University employs 2.600 researchers.

W: www.radboudumc.nl